2017: Avelumab in patients with newly diagnosed GBM (Phase II)
Future Trial
This is some text inside of a div block.
Glioblastoma Multiforme
GBM typically presents with headaches, new onset seizures, nausea, vomiting or cognitive dysfunction. Median survival without treatment is approximately six months. Conventional therapy consisting of surgery, radiotherapy, and Temozolomide chemotherapy extends median survival to 14 months.
We offer a multidisciplinary approach to patients with GBM. Our neurologists in conjunction with other specialists; oncologists and neurosurgeons are involved in the diagnosis and medical treatment of the tumor and its complications such as seizures. Motor deficits affecting ambulation can be improved with neuro rehab via our in house NeuroGym.
CNO is currently looking at using non-invasive neuromodulation (NINM) via repetitive transcranial magnetic stimulation (rTMS) to improve outcomes in patients with GBM.
CNO offers a multidisciplinary approach to patients with GBM. Our neurologists in conjunction with other specialists; oncologists and neurosurgeons are involved in the diagnosis and medical treatment of the tumor and its complications such as seizures, our patients benefit from personalized neurorehabilitation through our in-house NeuroGym rehabilitation program, designed to help improve motor deficits affecting ambulation.
CNO is currently looking at using non invasive neuromodulation (NNIM) via repetitive transcranial magnetic stimulation (rTMS) to improve outcomes in patients with GBM.
Experimental treatments can be accessed via our clinical trials. CNO previously initiated and conducted a clinical trial which looked at combining immunotherapy with conventional therapies.
